Healthcare Distribution Alliance (HDA) Senior Vice President of Communications John Parker released the following statement on the release of the Drug Enforcement Administration’s (DEA) Automation of Reports and Consolidated Orders System (ARCOS) data.
A new report published by the HDA Research Foundation concludes that federal proposals to permit the importation of prescription drugs into the U.S. fail to provide comprehensive guidance and funding to meet current federal safety and quality standards. As highlighted in the report, “The Risks and Realities of Commercial Drug Importation,” implementation of these policies would result in at least $1.1 billion in costs due to patient risks, required federal regulatory oversight and the operational challenges placed on the supply chain.
60 Minutes has consistently presented misleading, inaccurate accounts of pharmaceutical distributors’ role in the opioid abuse crisis. The latest episode perpetuates a number of myths around the opioid epidemic and does a disservice to any effort to truly understand and address its root causes — notably, the shift in medical practice to treat pain more aggressively and the role of illegal drugs in most overdose deaths.
The Healthcare Distribution Alliance (HDA) issued the following statement in response to the Rhode Island Legislature’s inclusion of a $5 million fee on prescription opioids in the state budget.
The Healthcare Distribution Alliance (HDA) honored pharmaceutical and consumer product manufacturers with the annual Distribution Industry Awards for Notable Achievements in Healthcare (DIANA). The honorees were formally recognized during the DIANA and Nexus Awards dinner at the HDA 2019 Business and Leadership Conference in Orlando, Fla.
John Parker
(703) 885-0216
Farah Simonett
(703) 885-0269
